Anti-SENP3 antibody [EP4360],Abcam,AB124790
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .
Host
Rabbit
Reactivity
Human
Application
WB
Platform ID
BAB780325937
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Protease that releases SUMO2 and SUMO3 monomers from sumoylated substrates, but has only weak activity against SUMO1 conjugates (PubMed : 16608850, PubMed : 32832608, PubMed : 36050397). Deconjugates SUMO2 from MEF2D, which increases its transcriptional activation capability (PubMed : 15743823). Deconjugates SUMO2 and SUMO3 from CDCA8 (PubMed : 18946085). Redox sensor that, when redistributed into nucleoplasm, can act as an effector to enhance HIF1A transcriptional activity by desumoylating EP300 (PubMed : 19680224). Required for rRNA processing through deconjugation of SUMO2 and SUMO3 from nucleophosmin, NPM1 (PubMed : 19015314). Plays a role in the regulation of sumoylation status of ZNF148 (PubMed : 18259216). Functions as a component of the Five Friends of Methylated CHTOP (5FMC) complex; the 5FMC complex is recruited to ZNF148 by methylated CHTOP, leading to desumoylation of ZNF148 and subsequent transactivation of ZNF148 target genes (PubMed : 22872859). Deconjugates SUMO2 from KAT5 (PubMed : 32832608). Catalyzes desumoylation of MRE11 (PubMed : 36050397). See full target information SENP3
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
Please provide the required information below so that we can quickly source your products.